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Abstract
Background: Magnetic nanoparticles (MNPs) offer a large range of applications in life sciences. Applications in
neurosciences are one focus of interest. Unfortunately, not all groups have access to nanoparticles or the possibility
to develop and produce them for their applications. Hence, they have to focus on commercially available particles.
Little is known about the uptake of nanoparticles in primary cells. Previously studies mostly reported cellular uptake
in cell lines. Here we present a systematic study on the uptake of magnetic nanoparticles (MNPs) by primary cells
of the nervous system.
Results: We assessed the internalization in different cell types with confocal and electron microscopy. The analysis
confirmed the uptake of MNPs in the cells, probably with endocytotic mechanisms. Furthermore, we compared the
uptake in PC12 cells, a rat pheochromocytoma cell line, which is often used as a neuronal cell model, with primary
neuronal cells. It was found that the percentage of PC12 cells loaded with MNPs was significantly higher than for
neurons. Uptake studies in primary mixed neuronal/glial cultures revealed predominant uptake of MNPs by
microglia and an increase in their number. The number of astroglia and oligodendroglia which incorporated MNPs
was lower and stable. Primary mixed Schwann cell/fibroblast cultures showed similar MNP uptake of both cell
types, but the Schwann cell number decreased after MNP incubation. Organotypic co-cultures of spinal cord slices
and peripheral nerve grafts resembled the results of the dispersed primary cell cultures.
Conclusions: The commercial MNPs used activated microglial phagocytosis in both disperse and organotypic
culture systems. It can be assumed that in vivo application would induce immune system reactivity, too. Because of
this, their usefulness for in vivo neuroscientific implementations can be questioned. Future studies will need to
overcome this issue with the use of cell-specific targeting strategies. Additionally, we found that PC12 cells took up
significantly more MNPs than primary neurons. This difference indicates that PC12 cells are not a suitable model for
natural neuronal uptake of nanoparticles and qualify previous results in PC12 cells.
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Background
Nanoparticles have recently received increased attention
in the life sciences. Because of their small size, their cel-
lular uptake mechanisms such as endocytosis [1,2] and
the possibility to functionalize them with biofunctional
active groups, nanoparticles offer a large range of applica-
tions [3-5]. They can be tagged with cell-specific target
sites [6,7] and if they are magnetic, they can be moved
and influenced by an external magnetic field [8]. One
example of these features is cellular hyperthermia of
tumours, a novel clinical protocol in which the MNPs are
heated up by an alternating magnetic field and tumour
cells are destroyed by thermal energy [9].
Another interesting application of magnetic nanoparti-
cles is magnetofection™. This technique uses them as a
carrier for nucleic acids and enhances cell transfection
with an external magnetic field [10]. MNPs are already
routinely used for contrast enhancement in magnetic
resonance imaging, drug delivery, magnetic cell separa-
tion, and tissue repair studies [3,11].
One idea for an application in neuroscience is the use
of MNPs to promote regeneration within the peripheral
(PNS) and central nervous system (CNS). The outcome
after injury repair in the nervous system is often poor,
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pate in the regeneration of the injured nerve. After a per-
ipheral nerve lesion, the axon distal from the injury site
degenerates and Schwann cells and later macrophages
clean the neural tubes of cell debris and myelin, the so-
called Wallerian degeneration. Additionally, Schwann
cells produce growth factors and form bands of Büngner
as guiding paths for the regrowing axons, building a
regeneration-promoting environment [14].
In the CNS, regeneration of injured axons is even more
difficult. Unlike Schwann cells, oligodendroglia do not
show phagocytic activity. Therefore, an inhibitory envir-
onment for axonal regeneration is evident and the clear-
ance of the injury site of cell and myelin debris is much
slower than in the PNS. Additionally, the regeneration-
promoting environment produced by the Schwann cells
in the PNS is absent [15].
Nanoparticles now offer the possibility to influence such
processes locally. Mittnacht et al. [16] for example deliv-
ered RhoA-specific siRNA by nanoparticles into PC12
cells as a neuronal cell model. Thereby, they suppressed
the signal transduction pathway for inhibitory proteins,
resulting in enhanced neurite outgrowth of the PC12 cells
after stimulation with nerve growth factor (NGF). In con-
trast, Hamasaki et al. [17] used magnetically labelled
neural progenitor cells, which were located by an external
magnetic field, to promote axon growth in organotypic
co-cultures of brain cortex and spinal cord.
Although there is a trend to use self-produced nanopar-
ticles, reproducibility among different studies would be
higher if not every study was based on distinct particles.
Thus, we used commercially available MNPs and analyzed
their uptake in cells of the nervous system. Unfortunately,
there is little literature concerning primary cell cultures
and nanoparticles, especially with a neuroscientific back-
ground. Mostly, previous studies used different kinds of
cell lines such as PC12 as a neuronal model [16,18],
human umbilical vein endothelial cells (HUVECs) [19]
and Infinity™ telomerase-immortalised primary human
fibroblasts (hTERT-BJ1) [4,20]. However, cell lines are
often tumour cells or immortalised cells, behaving differ-
ently than primary cells [21,22].
For this reason, we compared neuronal differentiated
PC12 cells with primary neuronal cells according to their
uptake of green fluorescent MNPs. Primary neuronal cells
were used from rat mixed neuronal/glial cerebellar cell
cultures. These neuronal cells are mainly granular neurons
cultured in a more in vivo like environment having cell
contacts with different kinds of glial cells occurring in the
cerebellum. Thus, we analyzed the uptake of MNPs for
the different kinds of glial cells, too. Together with the
analysis of rat primary cell cultures of the PNS, mixed
Schwann cell/fibroblast cultures, both culture systems give
a good idea which cells will take up nanoparticles in vivo
for a future therapeutic approach.
To verify our results in the dispersed cell cultures,
organotypic co-cultures of spinal cord slices and periph-
eral nerve grafts as a more complex model were addition-
ally analyzed. The organotypic co-cultures mimic the
tissue architecture of both parts of the nervous system
and allow screening of the cellular uptake of MNPs in a
more tissue-like environment.
Methods
Magnetic nanoparticles
Commercial green fluorescent MNPs produced by Che-
micell (4415 nano-screenMAG-ARA, Berlin, Germany)
were used. These MNPs have a magnetite core covered
by a lipophilic green fluorescent dye and a polysaccharide
matrix of glucuronic acid, a derivate of glucose, for addi-
tional functionalization. Because of the carboxyl group of
the coating polymer, the particles become anionic in
solution. Zeta potential measurements of these MNPs
suspended in cell culture media revealed a negative
charge on the particles; this finding was also observed in
the presence of serum supplement. MNPs were diluted
the day before use with three different serum-supplemen-
ted media: For primary cell cultures MNPs were diluted
in Dulbecco’s modified Eagle medium (DMEM) medium
with 10% fetal calf serum (FCS), 6 g/l D-glucose and 1%
penicillin/streptomycin (pen/strep), resulting in a hydro-
dynamic MNP diameter of 190 nm (± 2 nm) and a zeta
p o t e n t i a lo f- 6 . 1m V .P C 1 2c e l l sw e r ec u l t u r e dw i t h
MNPs diluted in Roswell Park Memorial Institute
(RPMI) medium with 10% FCS, 50 ng/ml NGF (Sigma,
S t .L o u i s ,U S A ) ,2m ML - g l u t a m i n ea n d1 %p e n / s t r e p ,
yielding a hydrodynamic MNP diameter of 199 nm (± 1
nm) and a zeta potential of -40.0 mV. For the organoty-
pic co-cultures, MNPs were diluted in 50% Eagle’sm i n i -
mal essential medium (MEM), 25% Hank’s balanced salt
solution (HBSS), 25% FCS, 33.3 mM D-glucose, 1% pen/
strep and 100 ng/ml recombinant rat glia cell line-
derived neurotrophic factor (GDNF, R&D systems,
Minneapolis, USA) giving a hydrodynamic diameter of
185 nm (± 1 nm) and a zeta potential of -12.8 mV.
Animal care
All animal experiments were carried out in accordance
with the guidelines of the German Animal Welfare Act.
The study was approved by the Animal Care and Use
Committees of Saxony-Anhalt. Formal approval to con-
duct the experiments described was obtained from the
animal subjects review board of our institution and can
be provided upon request. All efforts were made to
minimize the number of animals used and their
suffering.
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5-8 day neonatal rats were decapitated and the cerebel-
lum was separated. Meninges were removed in serum-
free DMEM containing 6 g/l D-glucose and 1% pen/
strep. Subsequently, the cerebelli were mechanically dis-
sociated (18 and 23 gauge needles) in serum-free DMEM
and centrifuged at 1500 rpm for 5 min. Cells were resus-
pended in serum-supplemented DMEM with 10% FCS,
6 g/l D-glucose, 1% pen/strep, counted and seeded for
immunocytochemistry in 12-well plates with 1*10
6 cells
per well on poly-D-lysine-coated coverslips (18 or
15 mm). For viability assay, cerebellar cells were seeded
in poly-D-lysine-coated Petri dishes (35 mm) with a cell
density of 2.5*10
5 cells per dish.
Cells were incubated at 37°C in a humidified 6% CO2
atmosphere and medium was changed 24 h after pre-
paration to remove cell debris.
For the uptake quantification based on immunocyto-
chemistry, the medium was replaced with MNP medium
(50 μg/ml MNPs) at different time points depending on
cell type and different proliferation patterns of the var-
ious cell types. For example, the number of neurons
decreases over the first week in cerebellar cultures
[23,24] and oligodendroglia differentiate from precursor
cells after more than one week [25-27]. Quantification of
our mixed cerebellar cultures respective the culture com-
position revealed that they are composed of 45.5% (±
16.7%) astroglia, 32.1% (± 19.2%) microglia, 24.3% (±
14.6%) neurons and no oligodendroglia on day in vitro
(DIV) 5. On DIV 7, they contain 35.2% (± 17.3%) micro-
glia, 32.5% (± 17.2%) astroglia, 13.7% (± 10.4%) neurons
and 2.1% (± 3.4%) oligodendroglia. On DIV 13, they are
composed of 48.4% (± 28.4%) microglia, 38.3% (± 24.8%)
astroglia, 1.5% (± 2.8%) neurons and 3.0% (± 4.1%)
oligodendroglia.
To quantify the uptake of neurons, MNP medium was
added on DIV 4. MNP uptake in astroglia and microglia
was analyzed on DIV 7 and in oligodendroglia on DIV
13. Simultaneously, MNP-free medium was added to
control cells.
For viability assay 10, 50 or 100 μg/ml MNP-containing
medium was added to the cultures on DIV 6. At the
same time, MNP-free medium was added to control cells.
Cells were incubated for 24 h, washed with phosphate
buffered saline (PBS) and used further for immunocyto-
chemistry or for viability assay.
Schwann cell/fibroblast cultures
5-7 day old rats were decapitated, the spinal ganglia were
taken out and collected in a solution of 2 ml serum-free
DMEM (6 g/l D-glucose, 1% pen/strep), 40 μl collagenase
(0.05%), 100 μl hyaluronidase (0.1%) and 2 ml dispase II
(1.25 U/ml). In this enzyme-supplemented medium the
isolated spinal ganglia wer ei n c u b a t e da t3 7 ° Ci na6 %
CO2 humidified atmosphere for ca. 3.5 h to dissociate the
cells enzymatically. The cells were additionally disso-
ciated mechanically using injection needles (18 and 23
gauge needles) and centrifuged at 1500 rpm for 5 min.
Afterwards the cells were resuspended in serum-supple-
mented medium (DMEM, 10% FCS, 6 g/l D-glucose, 1%
pen/strep).
For immunocytochemistry, 18 or 15 mm coverslips in
12-well plates were coated with laminin (0.05 mg/ml)
before seeding 5*10
4 cells per well.
For viability assay cells were seeded on laminin-coated
Petri dishes (35 mm) with a cell density of 2.5*10
5 cells
per dish.
Cells were incubated at 37°C in a humidified 6% CO2
atmosphere and the medium was changed 24 h after pre-
paration to remove cell debris. Culture composition was
quantified and revealed 62.7% (± 17.0%) Schwann cells
and 37.3% (± 17.0%) fibroblasts on DIV 7. For immuno-
cytochemistry and viability assay, the medium was
replaced with MNP medium on DIV 6. MNP medium
contained 50 μg/ml MNPs for immunocytochemistry and
10, 50 and 100 μg/ml MNPs for the viability assay. MNP-
free medium was added to control cells. After 24 h, cells
were washed with PBS and used further.
Cell line
PC12 cells were seeded on poly-D-lysine coated culture
flasks and cultured with RPMI medium supplemented
with 10% FCS, 2 mM L-glutamine and pen/strep. After
24 h, cells were differentiated with 50 ng/ml NGF for
6 days. Differentiated cells were seeded afterwards in
12-well plates with 1.25*10
5 cells per well on poly-D-
lysine coated coverslips and kept in differentiation med-
ium for 3 days before the medium was replaced with
differentiation medium supplemented with 50 μg/ml
MNPs. After 24 h, cells were washed with PBS and
fixed for immunocytochemistry.
Organotypic spinal cord co-cultures
Organotypic spinal cords co-cultured with peripheral
nerve grafts were prepared according to Vyas et al. [28]
with slight modifications. For the cultures, neonatal rats
of postnatal day 3-4 were used. Rats were decapitated,
the spinal cords excised and roots and meninges removed
in dissection buffer (HBSS, 3.4 mM NaHCO3,1 0m M
HEPES, 33.3 mM D-glucose, 5.8 mM MgSO4, 0.03%
bovine serum albumin (BSA), 1% pen/strep).
The lumbar part of the spinal cord was cut into 350 μm
transverse sections with a McIlwain tissue chopper
(Mickle Laboratory Engineering, Gomshall, UK). About
1 0u s a b l es e c t i o n sc o u l db eo b t a i n e df r o mo n el u m b a r
spinal cord part. Three slices were cultured on one Milli-
cell membrane insert (Millipore, Billerica, USA) placed in
6-well plates. Each well contained 1 ml of medium
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D-glucose, 1% pen/strep and 100 ng/ml GDNF to keep
the motor neurons in the culture alive.
To enhance the motor neuronal survival and to guide
sprouting neurites, a co-culture of the spinal cord slice
with a peripheral nerve graft as a reconstructed ventral
root was chosen.
As peripheral nerve graft, pieces of ulnar and median
nerves were harvested from the same animals and one
graft was opposed to the ventral surface of each spinal
cord slice.
To check the contribution of MNPs in the tissue
slices, 100 μg/ml MNPs were added to the medium for
the whole culture time. Co-cultures were incubated at
37°C in humidified 6% CO2 atmosphere. The medium
was changed 24 h after preparation and afterwards every
second day.
Immunocytochemistry of cell cultures
Staining procedure
After 24 h MNP incubation, cells were washed once with
PBS to remove free-floating MNPs and fixed for 30 min
with 4% paraformaldehyde (PFA). Fixing was followed by
three times washing with PBS. Unspecific binding sides
were blocked for 1 h with 10% FCS, 0.3% Triton-X in PBS.
Subsequently, cells were incubated with the primary anti-
body overnight at 4°C. Cell type specific primary antibo-
dies were chosen: primary neurons were stained with
mouse monoclonal anti-microtubule associated protein-2
(MAP2, 1:1000, Sternberger Monoclonals, Baltimore,
USA), PC12 cells with rabbit polyclonal anti-ß-III-tubulin
(1:1000, Covance, Princeton, USA), microglial cells with
mouse monoclonal anti-CD11b/c (1:400, BD Pharmigen,
Franklin Lakes, USA) or with rabbit polyclonal anti-
ionized calcium binding adaptor molecule 1 (IBA-1,
1:1000, Wako Pure Chemicals Industries, Osaka, Japan),
astroglia with rabbit polyclonal anti- glial fibrillary acidic
protein (GFAP, 1:500, Progen, Heidelberg, Germany) and
oligodendroglia with mouse monoclonal anti-galactocer-
ebroside (1:250, Chemicon, Billerica, USA). Schwann cells
were stained with rabbit polyclonal anti-S100 (1:200,
DAKO, Glostrup, Denmark) and fibroblasts with mouse
monoclonal anti-fibronectin (1:200, Abcam, Cambridge,
UK) antibody. Primary antibodies were diluted in PBS
containing 0.3% Triton-X and 1% FCS.
After incubation overnight, cells were washed three
times with PBS and incubated for 3 h with an anti-rabbit
or anti-mouse Alexa Fluor 546 Dye secondary antibody
(Invitrogen, Carlsbad, USA) diluted 1:200 in PBS. Cells
were washed again three times with PBS and cell nuclei
were counterstained with 4’, 6-diamidino-2-phenylindole
(DAPI, 1 μg/ml diluted in PBS, Roche Applied Science,
Indianapolis, USA). After washing again with PBS,
coverslips were embedded with Immu-Mount (Thermo
Scientific, Waltham, USA).
Quantification
To quantify the cellular uptake cell type specific antibodies
were used to stain cell lines followed by counterstaining all
nuclei with DAPI. Control coverslips (4-5) and 10 cover-
slips of the MNP-incubated cells were used and 4-5 ran-
dom images per coverslip (each corner and middle) were
taken. Images were acquired with an AxioImager micro-
scope (Zeiss, Jena, Germany). Total cell number (given by
the DAPI-staining), the number of cell type specific
stained cells (for example neurons) and the number of
cells which were co-localized with the green fluorescent
MNPs were counted with the AxioVision Rel. 4.8 Imaging
software by Zeiss. Values were calculated as a percentage
to the total cell number providing the percentage specific
cell types in the cultures. Total uptake was calculated as
percentage of specific cell type with MNP co-localization
to the total number of this specific cell type.
In PC12 cells, the total cell number, the number of
clearly differentiated cells (cells with ß-III-tubulin
expression and neurite growth) and the number of dif-
ferentiated cells co-localized with MNPs was quantified
and calculated in a similar manner.
Statistical analysis was performed with Graph Pad Prism
4 (GraphPad Software, La Jolla, USA) using an unpaired
t-test for the comparison of control and MNP group. For
each cell type n = 20 images from 4-5 coverslips were cho-
sen. For the comparison of the MNP uptake between the
different cell types in the cerebellar cultures a one-way
ANOVA followed by a Bonferroni post-hoc test was per-
formed (n = 40 images from 10 coverslips). The compari-
son of the MNP uptake between primary neurons/PC12
cells and between Schwann cells/fibroblasts was done with
an unpaired t-test (both n = 40 images from 10 coverslips).
In all statistical tests a p-value ≤ 0.05 was considered to be
statistically significant.
Immunohistochemistry of organotypic co-culture
Staining procedure
Cultures were fixed after one week by replacing the med-
ium with 4% PFA overnight. For immunohistochemistry,
the membranes of inserts were separated from the carrier
and cultures attached on membranes were stained free-
floating according to the protocol described above. As
primary antibodies mouse monoclonal anti-pan-neuronal
neurofilament marker (1:1000, Sternberger Monoclo-
nals), rabbit polyclonal anti-ß-III-tubulin (1:1000, Cov-
ance), mouse monoclonal anti-CD11b/c (1:400, BD
Pharmigen), rabbit polyclonal anti-GFAP (1:500, Progen),
rabbit polyclonal anti-S100 (1:200, DAKO) and rabbit
polyclonal anti-myelin basic protein (1:200, Chemicon)
were used to visualize the main cell types.
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Organotypic co-cultures were imaged with a TCS SPE
DMI4000 confocal microscope by Leica (Wetzlar,
Germany) and edited in the Leica Application Suite 2.3.
Figure 1 shows a phase contrast image of a spinal cord
co-culture. This picture was taken with a cell culture
microscope DMI3000 by Leica and was edited with
Photoshop CS4 (Adobe Incorporated Systems, San Jose,
USA) to create a collage of the whole co-culture. Images
of motor neurons were taken at the ventral part of the
spinal cord as marked in Figure 1 by the upper white
box. Images of other cell types were taken in the vicinity
of the intersection of the spinal cord slice and the
peripheral nerve graft, marked by the other boxes in
Figure 1.
Electron microscopy
Cultures were fixed for 24 h with 4% PFA. They were
washed with 0.1 M cacodylate buffer and incubated for
1 h with 1% osmium tetroxide, washed again with 0.1 M
cacodylate buffer and 50% ethanol and incubated with
2% uranyl acetate for 1 h. Subsequently, cells were dehy-
drated in an ascending ethanol series and embedded in
Durcupan™ ACM Fluka (Sigma, St. Louis, USA). After
hardening at 68°C, cell culture plastic was removed and
cells were cut in ultra-thin slices of 70 nm. Images were
taken with an EM 900 transmission electronic micro-
scope by Zeiss and edited with Adobe Photoshop CS4.
Viability assay of cell cultures
To reveal changes in cell viability of primary cell cultures
incubated with MNPs, an MTS (3-(4.5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-
razolium) proliferation assay (CellTiter 96 Aqueous one
solution cell proliferation assay by Promega, Madison,
USA) was used. To avoid previously reported and dis-
cussed interferences of nanoparticles with colorimetric
assays and absorbance measurement [29], the experimen-
tal protocol of the MTS assay was slightly changed. Cells
of both primary cell cultures were incubated on DIV 6 for
24 h with MNP medium containing different concentra-
tions of MNPs (10, 50 and 100 μg/ml, each with n = 10
for Schwann cell/fibroblast cultures and n = 12 for cere-
bellar cultures). Control cells received MNP-free medium.
After 24 h of incubation, the medium was removed and
cells were washed once with sterile PBS. New MNP-free
Figure 1 Phase contrast of an organotypic co-culture of spinal cord and peripheral nerve graft. Boxes indicate imaged regions for
confocal microscopic analysis of different cell types including neurons, microglia, astroglia, oligodendroglia and Schwann cells. Bar represents
500 μm.
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bated for 3 h at 37°C in humidified 6% CO2 atmosphere.
All values were normalized by the mean of the blank.
After incubation the absorbance was measured with a
Tecan M200 microplate reader (Tecan, Männedorf,
Switzerland) at 490 nm. Two values per Petri dish were
determined and the mean used for statistical analysis.
Statistical analysis was performed with GraphPad Prism 4
using a one-way ANOVA followed by Dunnett’s post-hoc
test. A p-value ≤ 0.05 was considered to be statistically
significant.
To check for integrity of the cell cultures, staining of
cells with nuclear fast red-aluminium sulphate and Prus-
sian blue was performed. Prussian blue stained iron-(III)
oxide and visualized remaining MNPs (Figure 2). Images
for each group were acquired with an AxioImager
microscope (Zeiss).
Results
Cellular uptake
In this study we used anionic MNPs for uptake analysis
in cells of the nervous system. Previous studies reported
that the uptake of anionic nanoparticles in cells is mainly
mediated by endocytosis [30]. Because of this, we initially
looked at the localization of MNPs using nuclear fast
red-aluminium sulphate and Prussian blue staining in
mixed cerebellar and Schwann cell/fibroblast cultures
(Figure 2). Cultures of the control (Figure 2A, C) and the
MNP group (Figure 2B, D) revealed no visual differences
in culture integrity and composition. MNPs showed
mainly cellular localization in the cerebellar cultures
(Figure 2B, arrows) and in Schwann cell/fibroblast cul-
tures (Figure 2D, arrows). To look in more detail, we
used confocal and electron microscopy. Confocal micro-
scopy demonstrated green fluorescent MNPs inside the
cells and 3-D projections illustrated that MNPs were
coplanar with the cell bodies and nucleus (Figure 3). The
amount of MNPs inside cells fluctuated between the cell
types; e.g. microglia (Figure 3A) displayed a high amount
of MNPs whereas PC12 cells (Figure 3B) and Schwann
cells (Figure 3C) took them up to a lesser extent. Electron
microscopy revealed an accumulation of MNPs in intra-
cellular vesicular compartments in microglial cells
(Figure 4A, arrows) and Schwann cells (Figure 4B,
arrow), confirming an endocytotic uptake mechanism.
Cell cultures
Mixed cerebellar cultures were incubated for 24 h with
MNPs on DIV 4. At this time point, mixed cerebellar
cultures contained 17.7% (± 1.7% SD) detected neurons
in the control cultures and 16.5% (± 2.2% SD) detected
neurons in the cultures incubated with MNPs.
Cultures of PC12 cells revealed 57.5% (± 4.4% SD)
clearly differentiated cells in the control and 53.4% (±
3.5% SD) differentiated cells in the cultures incubated
with the MNPs. Overall, incubation of primary neurons
Figure 2 Cellular visualization of MNPs. Primary cerebellar and Schwann cell/fibroblast cultures are stained with nuclear fast red-aluminium
sulphate (visualizing the cells) and Prussian blue (visualizing MNPs). (A) shows control (CO) cerebellar cells and (B) cerebellar cells incubated with
MNPs. (C) illustrates Schwann cell/fibroblast cultures of the control and (D) incubated with MNPs. Arrows indicate stained MNPs. Bars represent
50 μm.
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cell number of both cell types (primary neurons p =
0.69, n = 20, Figure 5A; unpaired t-test, PC12 cells p =
0.47, n = 20, Figure 5B).
The comparison of the uptake potential of neuronal
differentiated PC12 cells with primary neuronal cells
demonstrated that 76.9% (± 11.8% SD) of MNPs had
been uptaken in PC12 cells compared with only 12.8%
Figure 3 Representative confocal 3-D-projections of cells. Representative confocal 3D projections of a microglial cell in (A), PC12 cell in (B)
and Schwann cell in (C) with MNP uptake. Image rotation is shown from left (frontal) to right (side view). Green fluorescent MNPs rotated in
correlation to the nucleus and cell bodies. Additionally, MNPs were coplanar to the cell bodies indicating real uptake of MNPs in the cells. Bar
represents 5 μm in (A) and 25 μm in (B) and (C).
Figure 4 Electron microscopy of primary cells. Electron microscopy revealed accumulation of electronic dense MNPs in intracellular vesicular
compartments, indicated by arrows. (A) shows a microglial cell of primary cerebellar cultures and (B) primary Schwann cells with uptake. Bars
represent 2.5 μm.
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Representative fluorescent images of PC12 cells and
neurons with MNP uptake are shown in Figure 6. Con-
trol cells (PC12 cells in Figure 6A, primary neurons in
Figure 6C) illustrated no green fluorescence whereas
cells incubated with MNPs showed green fluorescent
MNPs co-localized with PC12 cells (Figure 6B) and pri-
mary neurons (Figure 6D).
Besides neurons, cerebellar cultures contain different
types of glial cells. For analysis of glia cells, we stained the
cultures for glia cell type specific antibodies on DIV 7. At
this time, cultures contained 35.4% (± 2.8% SD) microglia
in control cultures and 43.2% (± 2.5% SD) microglia in
cultures incubated with MNPs. MNP incubation for 24 h
increased the number of microglia by 7.8% (± 3.8% SD)
(unpaired t-test, p = 0.046, n = 20, Figure 7A). Astroglia in
control cultures represented 67.8% (± 3.0% SD) and in cul-
tures incubated with MNPs 67.7% (± 1.8% SD). No
changes in the amount of astroglia were induced by MNP
incubation (unpaired t-test, p = 0.98, n = 20, Figure 7B).
For analysis of oligodendroglia, the cultures were stained
on DIV 13 with an oligodendroglial marker. 6.9% (± 1.1%
SD) oligodendroglia were found in control cultures and
5.9% (± 1.0% SD) in cultures incubated with MNPs. The
percentage of oligodendroglia did not change by MNP
incubation (unpaired t-test, p = 0.52, n = 19, Figure 7C).
The comparison between the different cerebellar cell types
revealed significant differences in the number of cells
which took up MNPs (Figure 7D): 78.7% (± 12.2% SD) of
microglia, 41.0% (± 14.9% SD) of astroglia, 19.2% (± 23.9%
SD) of oligodendroglia and 12.8% (± 11.8% SD) of neurons
showed uptake of MNPs (one-way ANOVA, p < 0.001).
Representative images of glial cell types with MNP uptake
are shown in Figure 8. Microglia of control cultures are
illustrated in Figure 8A, astroglia in Figure 8C and oligo-
dendroglia in Figure 8E. All lacked green fluorescent sig-
nals. The green fluorescent MNPs are clearly seen in
cultures incubated with MNPs for 24 h (see microglia in
Figure 8B, astroglia in Figure 8D and oligodendroglia in
Figure 8F, arrows). The images also show differences in
Figure 5 Quantitative analysis of MNP uptake in PC12 cells and primary neurons. All values are expressed as mean ± SD. (A) compares the
percentage of primary neurons in cerebellar cultures and (B) the percentage of differentiated PC12 cells of control cells and cells after MNP
incubation. MNP incubation induced no changes in the number of neurons and PC12 cells. (C) compares the number of both cell types which
took up MNPs. Significantly more PC12 cells took up MNPs than primary neurons.
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Page 8 of 17the cellular uptake of MNPs. Stained microglia clearly
demonstrated a higher content of MNPs per cell than the
other cell types (Figure 8B, arrow).
Although there is an increase in cell number of micro-
glia in cultures incubated with MNPs, the viability assay
revealed no significant differences between control cells
and cells incubated with 10, 50 and 100 μg/ml MNPs
(data not shown) (one-way ANOVA, p > 0.05, n = 12).
Mixed Schwann cell/fibroblast cultures were used on
DIV 7 and contained 61.9% (± 3.3% SD) Schwann cells
in control cultures. The incubation with MNPs induced
a decrease of 17.1% (± 5.5% SD) in the number of
Schwann cells to 44.8% (± 5.5% SD) Schwann cells
(unpaired t-test, p = 0.012, n = 20, Figure 9A). 61.4% (±
4.4% SD) of fibroblast were found in the control cul-
tures and 73.5% (± 4.3% SD) in cultures incubated with
MNPs indicating a trend of an increased number of
fibroblasts (unpaired t-test, p = 0.054, n = 20) compared
to controls (Figure 9B). Nevertheless, Schwann cells
seem to be more sensitive to the MNPs then fibroblasts,
but their uptake capacity is similar: 61.1% (± 3.2% SD)
of Schwann cells and 58.1% (± 3.9% SD) of fibroblasts
showed uptake of MNPs after 24 h incubation time
(unpaired t-test, p = 0.544, n = 40, Figure 9C). Repre-
s e n t a t i v ei m a g e so fS c h w a n nc e l l sa n df i b r o b l a s t sw i t h
MNP uptake are illustrated in Figure 10. Schwann cells
and fibroblasts of the control cultures lacked green
fluorescent signals (Figure 10A, C), but cells incubated
with MNPs showed green fluorescent MNPs co-loca-
lized with the cells (see Schwann cells in Figure 10B and
fibroblasts in Figure 10D, arrows).
The viability assay revealed no significant differences in
viability between control cells and cells incubated with
10, 50 or 100 μg/ml MNPs for 24 h (data not shown)
(one-way ANOVA, p > 0.05, n = 10).
Organotypic co-cultures
Organotypic co-cultures of spinal cord and peripheral
nerves were used to verify the results of the dispersed
cultures of the CNS and PNS in a more complex model.
MNPs were not found inside of motor neurons and
their neurites (Figure 11A, B) or in Schwann cells guid-
ing sprouting neurites. Microglia revealed vesicular
accumulation of huge amounts of MNPs inside the cells
Figure 6 Representative fluorescent images of PC12 cells and primary neurons. PC12 cells in (A) and (B) were stained with an anti-ß-III-
tubulin antibody (in red). (A) shows control cells and (B) cells incubated with MNPs. Primary neurons in (C) and (D) were stained with an anti-
MAP2 antibody (in red). (C) demonstrates control cells, (D) cells incubated with MNPs. MNPs are fluorescent green and marked with arrows. Bar
represents 50 μm.
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Page 9 of 17(Figure 11C, D). Astroglia (Figure 11E, F) and oligoden-
droglia took up MNPs and showed single accumulation.
Thus, uptake in organotypic culture resembles the
uptake observed in dispersed cultures.
Discussion
Literature regarding primary cell cultures, especially of
the nervous system and nanoparticles, is limited. Most
previous studies in nanosciences use cell lines such as
PC12 as a neuronal model [16,18]. However, cell lines
are often tumour cells or immortalised cells behaving
differently than primary cells [21,22]. PC12 cells show a
reliable uptake of nanoparticles: Non-functionalized
polymer-coated nanoparticles were found to be interna-
lized in the cytoplasm in a highly non-specific manner
[31], without toxic effects. Pisanic II et al. [18]
demonstrated a qualitative proportional uptake of anio-
nic nanoparticles, indicating non-limited uptake for the
used concentrations. Even biological functions of PC12
cells could be influenced by nanoparticles. Hussain et al.
[32] for example, depleted dopamine and dopamine
metabolites with manganese oxide particles in a dose-
dependent manner. Comparing differentiated PC12 cells
and primary cerebellar neurons in our study, we found
significant differences in the uptake of MNPs. A high
cellular uptake was observed in the PC12 cells compared
with only about 13% in primary neurons. Obviously,
PC12 cells are a questionable choice for exploring the
response of neurons to nanoparticles and do not predict
neuronal uptake of primary neurons.
We used mixed cerebellar cultures to model interac-
tions of the major cell types of the CNS. They contain,
Figure 7 Quantitative analysis of mixed cerebellar cultures after 24 h incubation with 50 μg/ml MNPs. All values are expressed as mean
± SD. (A) shows the number of microglia of control cultures and cells incubated with MNPs after 24 h. The percentage of microglia increased
significant with MNP incubation. The number of astroglia, shown in (B), was not influenced by MNPs. No significant differences between both
groups were found for oligodendroglia in (C). In (D), a comparison of the uptake for all cell types is shown. The number of cells which took up
MNPs was highest for microglia, followed by astroglia, oligodendroglia and neurons.
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Page 10 of 17Figure 8 Representative fluorescent images of glia cells in cerebellar cultures. Cell type specific stainings are shown in red and MNPs in
green (arrows). Microglia were stained with anti-CD11b/c, shown in (A) and (B), astroglia with anti-GFAP, in (C) and (D), and oligodendroglia
with anti-GalC, in (E) and (F), antibodies. Glia cells in (A), (C) and (E) represent control cells, cells in (B), (D) and (F) were incubated with 50 μg/ml
MNPs for 24 h. Bar represents 50 μm.
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droglia, which all have the potential to internalize MNPs
[33-35]. However, the uptake of MNPs was distinct
between the different cell types of these primary cul-
tures. MNPs were found to be predominantly taken up
by microglia.
Microglial cells are resident macrophages of the CNS,
sensing cell damage and pathogens [36]. If microglia are
activated by a stimulus, they change their morphology,
up-regulate immunologically relevant molecules such as
chemokine receptors, major histocompatibility complex
molecules and phagocytic receptors [37,38], and phagocy-
tose possible pathogens. Lundqvist et al. [39] showed that
nanoparticles become surrounded by a protein corona if
they are suspended in blood plasma. Different particle
sizes and charges resulted in different coronas which were
composed for example of immunglobulins, lipoproteins
and complement factors. This protein corona results in an
opsonization of nanoparticles and phagocytosis by macro-
phages and microglia [40,41]. Given that the MNPs used
in this study were suspended in serum containing
medium, it is possible to assume an opsonization of the
MNPs by serum proteins which stimulate the microglia to
phagocytose. We found that nearly 80% of the microglia in
these cultures took up MNPs. Additionally, microglia pro-
liferate in response to pathogens [42,43]. This was demon-
strated in our study, too. The number of microglia
increased after incubation with MNPs. This indicates acti-
vation of the microglia through the MNPs and suggests a
problem for in vivo application. Microglia would phagocy-
tose the administered MNPs before they could target
other cells such as neurons. Additionally, they would
trigger immune responses and influence other cell types.
This could counteract with the goal to use the MNPs for
the promotion of nerve regeneration in pathological
conditions.
MNPs were also internalized by astroglia and oligoden-
droglia, but to a lesser extent. Phagocytosis is described
in the literature for both glia types, too. However, the
potential seems to be lower than for microglia and differs
in velocity between the cell types [44-47], which could
explain the different uptake of the glial cell types found
Figure 9 Quantitative analysis of primary Schwann cell/fibroblast cultures after 24 h incubation with 50 μg/ml MNPs. All values are
expressed as mean ± SD. In (A), the number of Schwann cells is compared between cells of the control and cells incubated with MNPs. MNP
incubation decreased the percentage of Schwann cells. The comparison of control cells and cells incubated with MNPs for fibroblasts is shown
in (B). The number of fibroblasts in the cultures was not influenced by MNP incubation. (C) shows the comparison of the uptake for both cell
types. The number of cells which took up MNPs was similar in both cell types.
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godendroglial precursor cells revealed a satisfying uptake
of different kinds of nanoparticles [33-35]. Purified cul-
tures just give information about single cell types and
lack the interactions between the various cell populations
that can be found in tissues. Also Pickard and Chari [33],
who showed robust nanoparticle uptake in purified pri-
mary microglia, pointed out the importance of studies
comparing and analyzing nanoparticle uptake in the
major cell populations of the CNS. Our study, using
mixed cultures of the CNS and PNS, bridges this gap and
take the interactions of the cell types into account. Addi-
tionally, Pickard and Chari [33] predicted in their study
“... that the rapid and extensive MNP uptake by endogen-
ous microglia could represent a significant ‘extracellular’
barrier to particle uptake by other neural cell subpopula-
tions.” The results of our study confirm their prediction.
As mentioned above, most MNPs were phagocytosed by
the microglial cells in the mixed cultures which presum-
ably reduce the amount of MNPs for uptake by other
cells.
The mixed Schwann cell/fibroblast cultures model the
PNS environment. The PNS environment and especially
the Schwann cells influence nerve regeneration in the
nervous system, too. Both cell types took up MNPs and
do not show phagocytosis under normal conditions. But
both cell types are able to activate phagocytic potential
with appropriate stimulation. Schwann cells are able to
activate phagocytic functions during injury of the nerve
and clear the injury site of cell and myelin debris
[14,48]. Also, in vitro, Schwann cells retain this function
and can be stimulated to phagocytose applied myelin
membranes within 1 h [49]. Fibroblasts, on the other
hand, reveal substantial phagocytosis in wounds as well
as under in vitro conditions [50-52]. In purified cultures,
both cell types revealed reliable uptake of different kinds
of nanoparticles [53,54].
Besides phagocytosis, different types of endocytotic
pathways or diffusion [48] of the negatively charged
MNPs, facilitated by positively charged membrane
domains [55], could also be possible mechanisms for the
cellular uptake of MNPs in astroglia, oligodendroglia,
Schwann cells and fibroblasts and might explain the parti-
cular MNP uptake of the different cell types in our
experiments.
Dispersed cultures do not model the in vivo situation and
environment in total. Cells grow in a monolayer and lack
certain cell-cell connections. Organotypic cultures offer a
more complex and tissue-like environment for the cells.
Due of this factor, they model the in vivo environment
Figure 10 Representative fluorescent images of all cell types of primary mixed Schwann cell/fibroblast cultures.C e l lt y p es p e c i f i c
stainings are shown in red and MNPs in green (arrows). Schwann cells in (A) and (B) are stained with anti-S100 antibody and fibroblasts in (C)
and (D) with anti-fibronectin antibody. Images (A) and (C) illustrate control cells without MNPs and images (B) and (D) cells after MNP
incubation. Bars represent 50 μm.
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Page 13 of 17Figure 11 Immunohistochemical staining of organotypic spinal cord co-cultured with peripheral nerve graft. Co-cultures were incubated
for one week with 100 μg/ml green fluorescent MNPs and were stained with anti-pan-neuronal neurofilament to visualize neurons, shown in
images (A) and (B). Neurons do not display co-localization with green fluorescent MNPs. Microglia in (C) and (D) were visualized with the
microglial marker anti-CD11b/c and demonstrated high amount of MNPs localized in vesicles. Astroglial cells in (E) and (F) were stained with
anti-GFAP antibody and showed moderate MNP co localization (arrows). Bars in (A) and (E) represent 75 μm, in (C) 50 μm and in (B), (D) and (F)
25 μm.
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our results of the dispersed primary cell cultures of the
CNS and PNS to the organotypic co-culture of spinal cord
slices (CNS) and peripheral nerve graft (PNS). The uptake
of MNPs was similar between both systems. MNPs were
internalized predominately in microglia of the spinal cord
slice, but not in neurons. Astroglia, oligodendroglia and
Schwann cells revealed uptake too, but again to a lesser
extent.
Cellular uptake of exogenous particles might induce
toxic effects. Toxicity of nanoparticles is a serious pro-
blem for biological and medical purposes. However,
nanoparticles are not basically toxic. In human dermal
fibroblasts, Gupta and Gupta [56] compared non-coated
superparamagnetic iron oxide nanoparticles with poly-
mer-coated particles and revealed a toxic effect of the
non-coated particles and no toxic effect of the coated
ones. On the other hand, Karlsson et al. [57] compared
different metal oxide nanoparticles of different sizes
concerning their influences on viability and mitochon-
drial and DNA damage. They found size- and metal
oxide-dependent toxic effects and reported low toxicity
of iron oxide particles. The MNPs used in this study
showed only low toxicity towards Schwann cells. This
would make them useful candidates for in vivo applica-
tions in the nervous system concerning toxicity at first
view.
Given that dissociated and organotypic cultures show
similar uptake results, it is likely that these commercial
MNPs, although they show low toxicity, will not be easy
to use in vivo i nt h en e r v o u ss y s t e m .T h e ya c t i v a t et h e
immune cells of the CNS and are phagocytosed by
microglia in high numbers. Thus, for targeting cells other
than microglia, the MNPs have to be tagged with a cell-
type specific marker. Additional functionalizing of MNPs
with receptor agonists for a receptor-mediated uptake
mechanism [58] or a more lipophilic coating to increase
membrane permeability can improve cell-specific uptake
[59]. Once the MNPs are taken up in a sufficient amount
and frequency by specific cells of the nervous system,
they can be used for locally influencing cell responses to
axonal injury, for example with the delivery of siRNA or
transplantation of supporting cells. Also, delivery of local
drugs, growth factors, hormones and extracellular matrix
molecules in and on the cell surface to influence cell
responses [49,60] is possible through manipulation of
MNP localization with an external magnetic field.
Conclusion
Nanoparticles offer a large range of applications in life
and neurosciences. Their functionality often depends on
the fact that they are internalized by cells. Thus, we ana-
lyzed the uptake of commercially available MNPs in
cells of the nervous system and were able to show that
PC12 cells differ in their uptake to primary neuronal
cells, and thus are not an appropriate choice for answer-
ing questions concerning the response of neurons to
nanoparticles. MNPs in primary cerebellar and in orga-
notypic co-cultures were found to be predominantly
taken up by microglia, suggesting a problem for in vivo
application of these commercial MNPs because of the
immune response. Future research needs to overcome
this immune system activation with cell-specific target-
ing and additional functionalization.
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